Both Moderna (MRNA Quick QuoteMRNA - Free Report) and BioNTech (BNTX Quick QuoteBNTX - Free Report) are leading biotechs at the forefront of messenger RNA (mRNA) technology. The companies rose to prominence with their respective COVID-19 vaccines, but their investment stories now extend well beyond the pandemic.

As COVID-19 vaccine demand continues to normalize, Moderna and BioNTech are looking to leverage their mRNA platforms to develop new therapies and vaccines, including treatments targeting cancer and other serious diseases. The success of these efforts could play an important role in determining each company's long-term growth prospects.

But which stock offers the more compelling investment opportunity today? Let's examine their fundamentals to determine which could be the better investment choice.

The Case for MRNA

The Massachusetts-based company has evolved considerably from its origins as a COVID-19 vaccine developer. Moderna initially became a commercial-stage company with its COVID-19 vaccine, Spikevax, but has since expanded into the respiratory vaccine market with its RSV vaccine, mResvia, and, more recently, entered the seasonal influenza vaccine space with mFlusiva. The company also has a flu/COVID-19 combination vaccine, mCombriax, approved in the European Union.

This gives Moderna a presence across three major respiratory vaccine categories and should gradually reduce its reliance on COVID demand. The broader respiratory pipeline also provides additional avenues for expansion, with vaccines for norovirus and bird flu in late-stage development.

Moderna is also developing its pipeline beyond respiratory diseases, with oncology emerging as a key growth driver. The company recently announced positive top-line results from a late-stage study evaluating intismeran autogene, its personalized mRNA cancer therapy being co-developed with Merck (MRK Quick QuoteMRK - Free Report) . The study, which evaluated intismeran in combination with Merck’s Keytruda in patients with completely resected, high-risk (Stage IIB-IV) melanoma, met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. Moderna and Merck plan to present the detailed results at ESMO on Oct. 24 and engage with regulators regarding potential filings.

The positive results represent an important potential catalyst for Moderna's oncology ambitions. Moderna and Merck are advancing intismeran across nine phase II and phase III studies spanning multiple tumor types, including non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma. The goal is to determine whether the approach that showed promise in melanoma can be replicated across different tumor types.

Moderna's oncology pipeline extends beyond intismeran. The company is developing mRNA-based cancer antigen therapies, a T-cell engager and a cell-therapy enhancer. These programs could provide additional avenues for growth if they demonstrate clinical and commercial potential. Beyond oncology, Moderna is applying its platform to other therapeutic areas, including rare diseases and autoimmune disorders.

However, competition remains a concern. Moderna faces established competitors across the respiratory markets it targets. In COVID-19 vaccines, it competes with Pfizer (PFE Quick QuotePFE - Free Report) /BioNTech and Sanofi. In RSV, mResvia competes with Pfizer's Abrysvo and GSK's Arexvy, while the seasonal influenza market is already well established, with Sanofi, CSL Seqirus and GSK among the major players. This competitive landscape could make it challenging for Moderna to translate its newer products into significant market share.

Pipeline setbacks pose another risk for the stock. Moderna recently announced that a late-stage study of its norovirus vaccine did not meet the statistical criteria for early success at the interim analysis. This prompted the company to prepare an additional cohort before reaching a final decision. Such setbacks highlight the inherent risks associated with the company’s broad pipeline and show that a large number of programs does not guarantee successful commercialization.

The Case for BNTX

Like Moderna, this German-based biotech is working to transition beyond its COVID-19 vaccine and build a more diversified business. While Comirnaty, which BioNTech developed with Pfizer, remains an important source of revenue, the company's longer-term growth prospects increasingly depend on its pipeline.

Unlike Moderna, BioNTech's oncology strategy extends beyond a single technology. The company is developing a range of approaches, including mRNA-based immunotherapies, antibody-drug conjugates (ADCs), bispecific antibodies and other targeted therapies. This diversified approach could provide BioNTech with multiple opportunities to establish new revenue streams as COVID-19 vaccine demand normalizes.

The company has built a broad late-stage oncology pipeline, with 14 ongoing pivotal studies across multiple tumor types. One of its most important assets is pumitamig, a bispecific antibody designed to target both PD-L1 and VEGF-A simultaneously. Developed in collaboration with Bristol Myers Squibb, pumitamig is being evaluated in seven pivotal studies across the ROSETTA development program, spanning cancers including NSCLC, triple-negative breast cancer, colorectal cancer and gastric cancer.

BioNTech is also advancing its oncology strategy through ADCs. An important candidate is trastuzumab pamirtecan, a HER2-targeting ADC being evaluated across separate late-stage studies for recurrent endometrial cancer and metastatic breast cancer. Another ADC, elfetabart drozuntecan, targets B7-H3 and is being evaluated in a phase III study for metastatic castration-resistant prostate cancer. These programs give BioNTech additional potential avenues for growth beyond its mRNA technology.

BioNTech is also developing its own personalized cancer therapy, autogene cevumeran, in collaboration with Roche.  However, the program recently faced a setback in colorectal cancer after an independent committee recommended terminating a phase II study following a numerical imbalance in overall survival between the treatment arms. Although another mid-stage study evaluating the therapy in pancreatic ductal adenocarcinoma remains ongoing, the setback highlights the clinical risks associated with BioNTech's oncology pipeline.

BioNTech's substantial financial resources provide a cushion as it continues to invest heavily in research and development. However, the company faces the same fundamental challenge as Moderna — COVID-19 vaccine demand is normalizing, increasing the importance of its pipeline in replacing lost revenue over time. BioNTech's ability to convert its oncology investments into commercially successful products will therefore be critical to its long-term growth.

Competition is another consideration. In COVID-19 vaccines, Comirnaty competes with Moderna, while BioNTech's oncology candidates face competition from established pharmaceutical companies and biotechnology firms developing competing immunotherapies, ADCs and targeted treatments. The breadth of BioNTech's pipeline provides several potential opportunities but also exposes the company to the risks associated with developing multiple novel therapies.

How Do Estimates Compare for MRNA & BNTX?

The Zacks Consensus Estimate for Moderna’s 2026 sales suggests 8.3% year-over-year growth, while the company’s loss per share is expected to widen by 17.1%.

MRNA’s bottom-line estimates for 2026 and 2027 have improved over the past 60 days.

Image Source: Zacks Investment Research

For BioNTech, the Zacks Consensus Estimate for 2026 sales suggests a decline of 33.5% year over year, while the bottom-line loss is expected to widen by 668.5%.

BNTX’s loss per share estimates for 2026 and 2027 have widened in the past 60 days.

Image Source: Zacks Investment Research

Price Performance and Valuation of MRNA & BNTX

Year to date, shares of Moderna have skyrocketed 590%, while those of BioNTech have risen nearly 4%. In comparison, the industry has climbed roughly 8%, as seen in the chart below.

Image Source: Zacks Investment Research

From a valuation standpoint, MRNA is trading at a premium compared to BNTX, based on the price/sales (P/S) ratio. Moderna’s shares currently trade at 32.10 times forward 12-month sales, higher than 10.06 times for BioNTech.

Image Source: Zacks Investment Research

MRNA or BNTX: Which Is a Better Pick?

Moderna and BioNTech each carry a Zacks Rank #3 (Hold), which makes choosing one over the other difficult. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

However, Moderna looks like the better pick of the two at present. While both companies are moving beyond COVID-19 vaccines, Moderna's transition appears further along. It already has approved products across RSV, seasonal influenza and a flu/COVID-19 combination vaccine, providing greater visibility beyond COVID-19. BioNTech, meanwhile, continues to rely heavily on Comirnaty for top-line growth as it advances its oncology pipeline.

Moderna's recent success with intismeran further strengthens its growth outlook. The personalized mRNA approach offers a differentiated avenue for oncology growth, while the upcoming detailed data should provide further insight into the therapy's potential across additional indications. While one could argue that BioNTech has a broad oncology pipeline spanning multiple modalities, these approaches are already being pursued by several large-cap pharma and biotech players, potentially creating greater competition as they advance.